Skip to main content
OpenTrials
Completed

NCT Number: NCT03425513

Hepatitis B Virus Prevalence and Risk Factors in Belgium

The aim of this study was to evaluate the current prevalence and risk factors of hepatitis B virus (HBV) infection in a multi-ethnic neighbourhood situated in Middle Limburg, Belgium. Additionally, the investigators will determine linkage of care in hepatitis B surface antigen (HBsAg) positive subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis B Blood-Borne Infections Communicable Diseases DNA Virus Infections Digestive System Diseases Hepadnaviridae Infections Hepatitis Hepatitis, Viral, Human Infections Liver Diseases Virus Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ziekenhuis Oost-Limburg

Genk, Limburg, 3600, Belgium

About this study

Although the HBV prevalence is generally low in Western countries, such as Belgium, pockets of higher HBV prevalence exist in areas with large immigrant populations. Therefore national prevalence figures can underestimate the burden of HBV infection. The prevalence of chronic HBV in the population-based study in 2003 is believed to be an underestimate due to under-representation of the non-Belgian population. Moreover, by this time there are no data regarding the risk factors for HBV infection in the general population of Belgium.

Even in low-prevalence areas such as Belgium, HBV prevention and control is a public health priority, particularly since safe and effective vaccines are available. The aim of this study was to evaluate the current prevalence and risk factors of HBV infection in a multi-ethnic neighbourhood situated in Middle Limburg, Belgium. Additionally, the investigators will determine linkage of care in hepatitis B surface antigen (HBsAg) positive subjects.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 70
  • Males and females

Exclusion criteria

/

Treatment and study plan

Hepatitis B serology

Diagnostic Test

A serum specimen will be taken and assessed for hepatitis B serology (HBsAg and anti-HBc antibodies).

Questionnaire

Other

Participants will be asked to fill in a questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.

Primary outcomes

  1. Seroprevalence of current HBV infection in the Middle Limburg population

    Time frame: 1 day

    Serum HBsAg

  2. Seroprevalence of past or current HBV infection in the Middle Limburg population

    Time frame: 1 day

    Serum anti-HBc antibodies

Secondary outcomes

  1. Assess risk factors for current HBV infection in the Middle Limburg population

    Time frame: 1 day

    Combine results from (1) serum HBsAg with (2) questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.

  2. Assess risk factors for past or current HBV infection in the Middle Limburg population

    Time frame: 1 day

    Combine results from (1) serum anti-HBc antibodies with (2) questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.

Sponsors and collaborators

Lead sponsor

Hasselt University

Other

Registry information

Official study title

Hepatitis B Virus Prevalence and Risk Factors in Middle Limburg Belgium: the Importance of Migration.

Acronym: HBVBE

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Feb 7, 2018
Registry last updated
Jan 27, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.